#INDP

Most Searched, Thursday November 20, 2025 – Crystal Equity Research

3 months ago

Most searched small-cap stocks, Thu Nov 20th - #EPSM #CLSK #RZLV #LAES #NVTX #QUBT #BTBT #CYPH #RXRX #EOSE #VZLA #DNN #BITF #SGBX #BBAI #ONDS #MUX #LAC #INDP #DPRO - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Wednesday November 12, 2025 – Crystal Equity Research

4 months ago

Most searched small-cap stocks, Wed Nov 12th - #LWLG #GPUS #BLMZ #NVTS #CMBM #RXRX #HIVE #BTBT #EOSE #CMCT #DNN #ONDS #BITF #QUBT #PLUG #LPTX #INDP #ENGN #BTCS #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Indaptus Therapeutics (Nasdaq: INDP) reported third quarter 2025 results and a corporate update on Nov 12, 2025. Key clinical and financing highlights include completion of a six-participant Safety Lead-In combining Decoy20 and tislelizumab, which the Safety Review Committee deemed tolerable at the current dose and schedule, while enrollment is paused pending further efficacy evaluations.Financials: the company reported $5.8M cash at Sept 30, 2025, raised $2.3M via an at-the-market facility in Sept 2025, converted $5.7M of June 2025 promissory notes in July 2025, and expects cash to fund operations into Q1 2026.

4 months ago

#INDP Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

Most Searched, Thursday November 6, 2025 – Crystal Equity Research

4 months ago

Most searched small-cap stocks, Thu Nov 6th - #RELY #JBLU #SLDP #ACVA #EOSE #RXRX #BTBT #NUAI #FTEL #NVTS #BITF #STGW #ONDS #DNN #PLUG #USAR #UAMY #INDP #IMRX #AREC - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Tuesday November 4, 2025 – Crystal Equity Research

4 months ago

Most searched small-cap stocks, Tue Nov 4th - #HIVE #PRLD #FUBO #LAC #DENN #RR #NVTS #RXRX #SRPT #IHRT #DNN #ONDS #PLUG #HTZ #INDP #HRTG #FNV #CMBM #BTCS #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Tuesday October 28, 2025 – Crystal Equity Research

4 months ago

Most searched small-cap stocks, Tue Oct 28th - #OGN #NVTS #BTBT #ONDS #RR #JBLU #LAES #BITF #DVLT #DNN #BBAI #ZIM #SANA #INDP #GPUS #ESPR #ERO #BYND #BMNR #ASST - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Monday October 27, 2025 – Crystal Equity Research

4 months ago

Most searched small-cap stocks, Mon Oct 27th - #UAMY #LAC #OGN #JBLU #RR #LAES #ONDS #NTLA #RECT #GSIT #HIVE #DVLT #USAR #PPTA #INDP #CAAS #BYND #BORR #ASST #ALLO - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Tuesday October 21, 2025 – Crystal Equity Research

4 months ago

Most searched small-cap stocks, Tue Oct 21st - #HIVE #RR #LAES #EOSE #RXRX #GSIT #BOF #DNN #RYOJ #BBAI #NERV #RANI #NVTS #INOD #INDP #DVLT #DNUT #CRML #BYND #BTCS - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Indaptus Therapeutics Provides Clinical Update Indaptus Therapeutics (Nasdaq: INDP) provided updates on its INDP-D101 clinical trial evaluating Decoy20. A patient receiving Decoy20 monotherapy achieved a Partial Response with reduced liver metastases in urothelial cancer, though the response was not sustained. The company has also initiated combination therapy with tislelizumab, dosing 7 patients in the initial safety cohort.Of the first three evaluable combination therapy patients, one showed stable disease while two experienced disease progression. Additionally, Indaptus raised $5.7 million through convertible promissory notes and warrants, which were later converted into common stock and pre-funded warrants in July 2025.

6 months ago

#INDP Indaptus Therapeutics Provides Clinical Update

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

Indaptus Advances Novel Cancer Treatment: Launches Combination Trial with $5.7M Fresh Capital Biotech firm initiates Phase 1b/2 trial combining Decoy20 with PD-1 inhibitor tislelizumab, backed by $5.7M financing. Clinical data expected by year-end. Learn more.

7 months ago

#INDP Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants Indaptus Therapeutics (Nasdaq: INDP), a clinical stage biotechnology company, has announced an additional sale of $3.4 million in convertible promissory notes and warrants. Combined with a prior sale of $2.3 million, the company has raised total gross proceeds of $5.7 million in this offering.The notes carry a 6% annual interest rate and will mature on July 28, 2026. They will convert to common stock at the earlier of 30 days after a reverse split effectiveness or one year from issuance. The conversion price will be 80% of the average closing price over five trading days, capped at $11.20. Warrants for 200% of conversion shares will be issued post-conversion and stockholder approval.Paulson Investment Company, LLC serves as the exclusive placement agent. The proceeds will fund research and development, including a Phase 1b/2 clinical trial, working capital, and general corporate purposes. The securities were offered through a private placement under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D.

8 months ago

#INDP Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

8 months ago

🚀 Exciting times for #INDP! Trading at $11.06, this biotech gem shows a slight bullish trend with an 8-day EMA of $11.17. Speculative interest is high after securing cancer trial funding. Consider going long at $11.00, targeting $12.00 & $13.50. Stay cautious! 📈 #Biotech #Stocks

0 0 0 0

8 months ago

🚀 Exciting times for #INDP! Trading at $11.06, this micro-cap is showing moderate bullish momentum with an 8-day EMA of $11.17 and RSI of 54.39. Recent $2.3M cancer trial funding boosts sentiment. Consider a long position at $10.80, targeting $12.50 & $14.00. Stay sharp! 📈 #FeetrAI

0 0 0 0

8 months ago

🚀 Exciting times for #INDP! With Phase 3 trials a success and whispers of a big pharma partnership, the stock is showing bullish momentum. Trading above key averages at $11.11, it's primed for gains. Targeting $12.50 & $13.50 with a stop at $10.50. Stay tuned! 📈 #FeetrAI

0 0 0 0

Indaptus Therapeutics Plans Massive 1:28 Reverse Split: What Shareholders Must Know Before June 26 Critical stock restructuring cuts 16M shares to 572K. Learn key dates, exchange ratios, and impact on your holdings before trading resumes. Get Details

8 months ago

#INDP Indaptus Therapeutics Announces Reverse Stock Split

www.stocktitan.net/news/INDP/indaptus-thera...

1 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

8 months ago

Most searched small-cap stocks, Mon Jun 23rd - #APLD #ZETA #WULF #INDO #RIG #BTE #VLRS #JBLU #CMPS #SSRM #QUBT #MGNX #MAAS #LEU #INDP #IDR #HUT #EVH #IREN #RXRX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

8 months ago

🚀 Big moves for #INDP! Trading volume is soaring, and with RSI below 30, it's looking oversold and ready to rebound. MACD is turning positive, hinting at a bullish breakout. Consider going LONG at $0.58, targeting $0.65 & $0.70. Stop loss at $0.55. Stay sharp! 📈 #FeetrAI

0 0 0 0

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants Indaptus Therapeutics (NASDAQ: INDP) has secured $2.3 million through a private placement of convertible notes and warrants, led by a healthcare-focused institutional investor, as part of a larger offering targeting up to $5 million. The notes, maturing on July 28, 2026, carry a 6% annual interest rate and will convert to common stock at 80% of the average closing price over five trading days, capped at $0.40 per share. Investors will receive warrants to purchase 200% of conversion shares, exercisable for five years at the notes' conversion price. The proceeds will fund research and development, including a Phase 1b/2 clinical trial, working capital, and general corporate purposes. Paulson Investment Company is serving as the exclusive placement agent for this offering.

9 months ago

#INDP Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

Breakthrough Cancer Trial: Indaptus Tests Novel Immunotherapy Combo for Checkpoint Inhibitor Resistant Tumors New Phase 1b/2 study combines Decoy20 with PD-1 inhibitor to potentially help patients unresponsive to checkpoint therapy. See preliminary results.

9 months ago

#INDP Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

Indaptus Launches Key Cancer Drug Combination Trial as Q1 Cash Drops to $3.9M - What's Next? New Phase 1b/2 trial combines Decoy20 with BeOne's Tislelizumab. Early data shows promising safety profile. Q1 loss narrows to $0.32/share. See funding outlook.

10 months ago

#INDP Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit Indaptus Therapeutics (INDP) announces that its Founder and Chief Scientific Officer, Dr. Michael Newman, will take a prominent role at the 6th Annual Cytokine-Based Drug Development Summit in Boston on May 15-16, 2025. Dr. Newman will serve as Chair of Day 2 and deliver a presentation on "Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy & its Impact on Toxicity & Efficacy" on May 15. He will also lead a panel discussion on pre-clinical models and deliver opening and closing remarks.The summit, hosted by HansonWade, brings together industry leaders to discuss cytokine drug development challenges and solutions. CEO Jeffrey Meckler highlighted that this invitation demonstrates recognition of the company's novel Decoy platform and Dr. Newman's leadership in cytokine research.

10 months ago

#INDP Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion Indaptus Therapeutics CMO Dr. Waltzman selected to moderate key clinical operations panel at prestigious CMO360 Summit. Learn about trial optimization insights.

11 months ago

#INDP Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0

Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial New Phase 1 data reveals Decoy20's broad immune activation and favorable safety profile. Indaptus expands program with BeiGene combination therapy trial for enhanced anti-tumor activity.

11 months ago

#INDP Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

www.stocktitan.net/news/INDP/indaptus-thera...

0 0 0 0